These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 29116404)
21. Pilot study on omega-3 fatty acids in type I diabetes mellitus. Landgraf-Leurs MM; Drummer C; Fröschl H; Steinhuber R; Von Schacky C; Landgraf R Diabetes; 1990 Mar; 39(3):369-75. PubMed ID: 2137803 [TBL] [Abstract][Full Text] [Related]
22. Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk? Nelson JR; True WS; Le V; Mason RP Postgrad Med; 2017 Nov; 129(8):822-827. PubMed ID: 28974128 [TBL] [Abstract][Full Text] [Related]
23. Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians. Bays H Drugs Today (Barc); 2008 Mar; 44(3):205-46. PubMed ID: 18536782 [TBL] [Abstract][Full Text] [Related]
24. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Barter P; Ginsberg HN Am J Cardiol; 2008 Oct; 102(8):1040-5. PubMed ID: 18929706 [TBL] [Abstract][Full Text] [Related]
25. Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3. Pirillo A; Catapano AL Drug Des Devel Ther; 2015; 9():2129-37. PubMed ID: 25914523 [TBL] [Abstract][Full Text] [Related]
26. Effects of concurrent therapy with policosanol and omega-3 fatty acids on lipid profile and platelet aggregation in rabbits. Gámez R; Máz R; Arruzazabala ML; Mendoza S; Castaño G Drugs R D; 2005; 6(1):11-9. PubMed ID: 15806713 [TBL] [Abstract][Full Text] [Related]
27. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia. Castaño G; Fernández L; Mas R; Illnait J; Gámez R; Mendoza S; Mesa M; Fernández J Drugs R D; 2005; 6(4):207-19. PubMed ID: 16050054 [TBL] [Abstract][Full Text] [Related]
28. Omega-3-fatty acids: Do they prevent cardiovascular disease? Mason RP; Sherratt SCR; Eckel RH Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101681. PubMed ID: 35739003 [TBL] [Abstract][Full Text] [Related]
29. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. Jacobson TA; Glickstein SB; Rowe JD; Soni PN J Clin Lipidol; 2012; 6(1):5-18. PubMed ID: 22264569 [TBL] [Abstract][Full Text] [Related]
30. The benefits of ω-3 supplementation depend on adiponectin basal level and adiponectin increase after the supplementation: A randomized clinical trial. Barbosa MM; Melo AL; Damasceno NR Nutrition; 2017 Feb; 34():7-13. PubMed ID: 28063515 [TBL] [Abstract][Full Text] [Related]
31. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Bays HE; Tighe AP; Sadovsky R; Davidson MH Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):391-409. PubMed ID: 18327998 [TBL] [Abstract][Full Text] [Related]
32. Comparison of the effects of simultaneous administration of vitamin C and omega-3 fatty acids on lipoproteins, apo A-I, apo B, and malondialdehyde in hyperlipidemic patients. Shidfar F; Keshavarz A; Jallali M; Miri R; Eshraghian M Int J Vitam Nutr Res; 2003 May; 73(3):163-70. PubMed ID: 12847992 [TBL] [Abstract][Full Text] [Related]
34. Omega-3 fatty acids for cardioprotection. Lee JH; O'Keefe JH; Lavie CJ; Marchioli R; Harris WS Mayo Clin Proc; 2008 Mar; 83(3):324-32. PubMed ID: 18316000 [TBL] [Abstract][Full Text] [Related]
35. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690 [TBL] [Abstract][Full Text] [Related]
36. Influence of three rapeseed oil-rich diets, fortified with alpha-linolenic acid, eicosapentaenoic acid or docosahexaenoic acid on the composition and oxidizability of low-density lipoproteins: results of a controlled study in healthy volunteers. Egert S; Somoza V; Kannenberg F; Fobker M; Krome K; Erbersdobler HF; Wahrburg U Eur J Clin Nutr; 2007 Mar; 61(3):314-25. PubMed ID: 16969378 [TBL] [Abstract][Full Text] [Related]
37. Dietary n-6 and n-3 fatty acid balance and cardiovascular health. Wijendran V; Hayes KC Annu Rev Nutr; 2004; 24():597-615. PubMed ID: 15189133 [TBL] [Abstract][Full Text] [Related]
38. Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia. Pirillo A; Catapano AL Int J Cardiol; 2013 Dec; 170(2 Suppl 1):S16-20. PubMed ID: 23856442 [TBL] [Abstract][Full Text] [Related]
39. Protective role of n6/n3 PUFA supplementation with varying DHA/EPA ratios against atherosclerosis in mice. Liu L; Hu Q; Wu H; Xue Y; Cai L; Fang M; Liu Z; Yao P; Wu Y; Gong Z J Nutr Biochem; 2016 Jun; 32():171-80. PubMed ID: 27142749 [TBL] [Abstract][Full Text] [Related]
40. Impact of n-3 fatty acids on endothelial function: results from human interventions studies. Egert S; Stehle P Curr Opin Clin Nutr Metab Care; 2011 Mar; 14(2):121-31. PubMed ID: 21252652 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]